| Serial Number | 97466475 |
| Word Mark | ALL IN |
| Filing Date | Monday, June 20, 2022 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, March 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 6, 2023 |
| Goods and Services | Manufacturing services for others in the fields of pharmaceutical preparations, biopharmaceutical preparations, biologics, drug products, DNA plasmids, advanced therapeutic medicinal products (ATMPs), principally cell and gene therapies intended for research, clinical and commercial use in humans for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting |
| Goods and Services | Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services in the field of production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, May 2, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, July 7, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | KING OF PRUSSIA, PA 19406 |
| Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | KING OF PRUSSIA, PA 19406 |
| Event Date | Event Description |
| Monday, March 4, 2024 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, March 4, 2024 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, August 1, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, June 6, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 6, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, May 17, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, May 3, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, May 2, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, May 2, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, May 2, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, May 2, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, May 2, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, May 2, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, May 2, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, May 2, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, April 5, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 5, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 5, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, March 29, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, March 29, 2023 | NON-FINAL ACTION E-MAILED |
| Wednesday, March 29, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, March 27, 2023 | ASSIGNED TO EXAMINER |
| Thursday, July 7, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 23, 2022 | NEW APPLICATION ENTERED |